

# Matthew R Gardner

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/8556636/matthew-r-gardner-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

22  
papers

562  
citations

13  
h-index

22  
g-index

22  
ext. papers

756  
ext. citations

11.6  
avg, IF

3.77  
L-index

#	Paper	IF	Citations
22	AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. <i>Nature</i> , <b>2015</b> , 519, 87-91	50.4	211
21	Associating HIV-1 envelope glycoprotein structures with states on the virus observed by smFRET. <i>Nature</i> , <b>2019</b> , 568, 415-419	50.4	92
20	Anti-drug Antibody Responses Impair Prophylaxis Mediated by AAV-Delivered HIV-1 Broadly Neutralizing Antibodies. <i>Molecular Therapy</i> , <b>2019</b> , 27, 650-660	11.7	25
19	Enhanced recognition and neutralization of HIV-1 by antibody-derived CCR5-mimetic peptide variants. <i>Journal of Virology</i> , <b>2012</b> , 86, 12417-21	6.6	21
18	AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. <i>Science Translational Medicine</i> , <b>2019</b> , 11,	17.5	20
17	Mutations derived from horseshoe bat ACE2 orthologs enhance ACE2-Fc neutralization of SARS-CoV-2. <i>PLoS Pathogens</i> , <b>2021</b> , 17, e1009501	7.6	20
16	A Bispecific Antibody That Simultaneously Recognizes the V2- and V3-Glycan Epitopes of the HIV-1 Envelope Glycoprotein Is Broader and More Potent than Its Parental Antibodies. <i>MBio</i> , <b>2020</b> , 11,	7.8	19
15	eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. <i>PLoS Pathogens</i> , <b>2017</b> , 13, e1006786	7.6	19
14	eCD4-Ig Variants That More Potently Neutralize HIV-1. <i>Journal of Virology</i> , <b>2018</b> , 92,	6.6	16
13	Mutations from bat ACE2 orthologs markedly enhance ACE2-Fc neutralization of SARS-CoV-2 <b>2020</b> ,		16
12	eCD4-Ig Limits HIV-1 Escape More Effectively than CD4-Ig or a Broadly Neutralizing Antibody. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	15
11	Conditional Regulation of Gene Expression by Ligand-Induced Occlusion of a MicroRNA Target Sequence. <i>Molecular Therapy</i> , <b>2018</b> , 26, 1277-1286	11.7	15
10	Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. <i>Current Opinion in HIV and AIDS</i> , <b>2017</b> , 12, 294-301	4.2	14
9	A double-mimetic peptide efficiently neutralizes HIV-1 by bridging the CD4- and coreceptor-binding sites of gp120. <i>Journal of Virology</i> , <b>2014</b> , 88, 3353-8	6.6	13
8	CD4-Induced Antibodies Promote Association of the HIV-1 Envelope Glycoprotein with CD4-Binding Site Antibodies. <i>Journal of Virology</i> , <b>2016</b> , 90, 7822-32	6.6	13
7	Promise and Progress of an HIV-1 Cure by Adeno-Associated Virus Vector Delivery of Anti-HIV-1 Biologics. <i>Frontiers in Cellular and Infection Microbiology</i> , <b>2020</b> , 10, 176	5.9	9
6	Diverse pathways of escape from all well-characterized VRC01-class broadly neutralizing HIV-1 antibodies. <i>PLoS Pathogens</i> , <b>2018</b> , 14, e1007238	7.6	9

5	Direct expression and validation of phage-selected peptide variants in mammalian cells. <i>Journal of Biological Chemistry</i> , <b>2013</b> , 288, 18803-10	5.4	9
4	Simian Immunodeficiency Virus SIVmac239, but Not SIVmac316, Binds and Utilizes Human CD4 More Efficiently than Rhesus CD4. <i>Journal of Virology</i> , <b>2017</b> , 91,	6.6	3
3	High concordance of ELISA and neutralization assays allows for the detection of antibodies to individual AAV serotypes.. <i>Molecular Therapy - Methods and Clinical Development</i> , <b>2022</b> , 24, 199-206	6.4	2
2	A Coreceptor-Mimetic Peptide Enhances the Potency of V3-Glycan Antibodies. <i>Journal of Virology</i> , <b>2019</b> , 93,	6.6	1
1	Estimation of the in vivo neutralization potency of eCD4Ig and conditions for AAV-mediated production for SHIV long-term remission.. <i>Science Advances</i> , <b>2022</b> , 8, eabj5666	14.3	